Eliem Therapeutics Shares Outstanding 2021-2024 | CLYM
Eliem Therapeutics shares outstanding from 2021 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Eliem Therapeutics Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
27 |
| 2022 |
26 |
| 2021 |
12 |
| 2020 |
2 |
Eliem Therapeutics Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-06-30 |
30 |
| 2024-03-31 |
28 |
| 2023-12-31 |
27 |
| 2023-09-30 |
27 |
| 2023-06-30 |
27 |
| 2023-03-31 |
26 |
| 2022-12-31 |
26 |
| 2022-09-30 |
26 |
| 2022-06-30 |
26 |
| 2022-03-31 |
26 |
| 2021-12-31 |
12 |
| 2021-09-30 |
16 |
| 2021-06-30 |
3 |
| 2021-03-31 |
3 |
| 2020-12-31 |
|
| 2020-09-30 |
2 |
| 2020-06-30 |
2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
